DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
The current trading session for DRIO is underway, with the asset's price at $7.13, experiencing a slight dip of -7 cents (-0.972%) from the previous close of $7.2. Trading volume is at $3,270, representing a 26.71% increase compared to the average. The asset's performance is being closely watched as the market approaches the closing bell.
DRIO's latest quarterly earnings report, announced on Tuesday, May 12th, revealed a consensus estimate EPS of -1.48. The company's revenue for the same period stood at $5.46 million. Notably, DRIO reported a net income of -$8.25 million, with an EPS of 17 cents, amidst various operating expenses totaling $10.51 million.
In terms of cash flow, DRIO showcased a net change in cash of -$6.83 million, with operating cash flow at -$6 million and capital expenditure at -$31,000. The company's ratios paint a mixed picture, with a net profit margin of -147.73% and return on equity at -13.22%. Additionally, the quick ratio stands at 2.6, while the price to earnings ratio is at -12.06.
DRIO's balance sheet indicates total assets of $103.28 million, with total liabilities at $40.90 million. Notably, the company holds $20.26 million in cash and cash equivalents, with a net debt of $11.55 million.
This comprehensive financial snapshot provides valuable insights into DRIO's current standing and performance metrics.